Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (221-230 of 348) with videos related to

Pageof 35
Sort By:
Mucosal Immunology|June 23, 2021
Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primatesShunsuke Sakai, Nickiana E Lora, Keith D Kauffman, et al.
Journal for Immunotherapy of Cancer|March 14, 2015
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré P Fay, Sabina Signoretti, Marcella Callea, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2009
Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cellsXueli Yuan, M Javeed Ansari, Francesca D'Addio, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 3, 2016
LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 DownregulationAlba Llibre, Constantino López-Macías, Teresa Marafioti, et al.
Cancer Research|September 15, 2017
PD-1 Status in CD8<sup>+</sup> T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck CancerBenjamin A Kansy, Fernando Concha-Benavente, Raghvendra M Srivastava, et al.
Oncotarget|September 23, 2016
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumorsYu Mei, Wenya Linda Bi, Noah F Greenwald, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivoJun Yang, Leonardo V Riella, Susanne Chock, et al.
Molecular Therapy Oncolytics|February 4, 2022
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse modelYufei Wang, Alicia Buck, Marion Grimaud, et al.
Frontiers in Immunology|March 31, 2022
The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental SettingsStinne R Greisen, Tue W Kragstrup, Jesper Skovhus Thomsen, et al.
Nature|June 1, 2023
Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistanceJoon Seok Park, Francesca S Gazzaniga, Meng Wu, et al.
Pageof 35

Showing results (221-230 of 348) with videos related to

Sort By:
Pageof 35
Mucosal Immunology|June 23, 2021
Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primatesShunsuke Sakai, Nickiana E Lora, Keith D Kauffman, et al.
Journal for Immunotherapy of Cancer|March 14, 2015
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker studyAndré P Fay, Sabina Signoretti, Marcella Callea, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2009
Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cellsXueli Yuan, M Javeed Ansari, Francesca D'Addio, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 3, 2016
LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 DownregulationAlba Llibre, Constantino López-Macías, Teresa Marafioti, et al.
Cancer Research|September 15, 2017
PD-1 Status in CD8<sup>+</sup> T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck CancerBenjamin A Kansy, Fernando Concha-Benavente, Raghvendra M Srivastava, et al.
Oncotarget|September 23, 2016
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumorsYu Mei, Wenya Linda Bi, Noah F Greenwald, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivoJun Yang, Leonardo V Riella, Susanne Chock, et al.
Molecular Therapy Oncolytics|February 4, 2022
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse modelYufei Wang, Alicia Buck, Marion Grimaud, et al.
Frontiers in Immunology|March 31, 2022
The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental SettingsStinne R Greisen, Tue W Kragstrup, Jesper Skovhus Thomsen, et al.
Nature|June 1, 2023
Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistanceJoon Seok Park, Francesca S Gazzaniga, Meng Wu, et al.
Pageof 35